70 likes | 77 Views
Phase 3b. Treatment-Naive. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 and Renal Disease RUBY-I. Pockros PJ, Gastroenterology. 2016;150:1590-8. Ombit asvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 & Renal Disease RUBY- I: Study Design.
E N D
Phase 3b Treatment-Naive Ombitasvir-Paritaprevir-Ritonavirand Dasabuvir in GT1 and Renal DiseaseRUBY-I Pockros PJ, Gastroenterology. 2016;150:1590-8.
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 & Renal DiseaseRUBY-I: Study Design Source: Pockros PJ, Gastroenterology. 2016;150:1590-8.
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 & Renal DiseaseRUBY-I: Regimens 0 12 24 Week GT 1an = 13 Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + Ribavirin SVR12 GT 1bn = 7 Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir SVR12 Drug DosingOmbitasvir-Paritaprevir-Ritonavir (25/150/100 mg once daily)+ Dasabuvir: 250 mg twice dailyRibavirin for patients not on hemodialysis: 200 mg once dailyRibavirin for patients on hemodialysis: 200 mg given 4 hours before each hemodialysis session Source: Pockros PJ, Gastroenterology. 2016;150:1590-8.
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 & Renal DiseaseRUBY-I: Baseline Characteristics Source: Pockros PJ, Gastroenterology. 2016;150:1590-8.
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 & Renal DiseaseRUBY-I: Baseline Results RUBY-I: SVR 12 Rates* 85/88 91/91 13/13 7/7 11/13 7/7 11/13 7/7 OBV/PTV/r + DSV = Ombitasvir-Paritaprevir-Ritonavirand Dasabuvir; RBV = ribavirin Source: Pockros PJ, Gastroenterology. 2016;150:1590-8.
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 & Renal DiseaseRUBY-I: Conclusions Source: Pockros PJ, Gastroenterology. 2016;150:1590-8.
This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.